Low-Income Countries Archives - Page 3 of 3

Novavax and SIPL to Develop 1 Billion Covid-19 Vaccine Doses for India, Other Countries

Agreements, Antibodies, Business, Clinical Trials, COVID-19 Vaccines, India, Licensing, Low-Income Countries, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.

Novartis to provide ‘no profit’ COVID-19 drugs to low-income countries

Antibiotics, Business, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Drug Pricing, Generics, Gout, Heart Failure, Low-Income Countries, Supply Chain, World Bank

Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.

AstraZeneca Commits to 2 Billion Doses of COVID-19 Vaccine

Business, COVID-19 Vaccines, Distribution, Low-Income Countries, Manufacturing, Oxford University, United Kingdom, United States

AstraZeneca announced plans to manufacture 2 billion doses of the University of Oxford’s COVID-19 vaccine, AZD122.